{"Title": ["Halozyme Therapeutics Inc (HALO) Q1 2020 Earnings Call Transcript", "Biotech Stocks Facing FDA Decision In May 2020", "HALO Crosses Above Average Analyst Target", "First Week of May 15th Options Trading For Halozyme Therapeutics (HALO)", "Tuesday 3/24 Insider Buying Report: HALO, AFL", "Halozyme Therapeutics is Now Oversold (HALO)", "HALO Makes Notable Cross Below Critical Moving Average", "Can Halozyme Therapeutics Continue Its Momentum in 2020?", "Halozyme Therapeutics Inc (HALO) Q1 2020 Earnings Call Transcript", "Interesting HALO Put And Call Options For September 18th", "HALO Crosses Above Average Analyst Target", "Health Care Sector Update for 11/14/2019: REPL,HALO,AXNX,CGC,WEED.TO", "Health Care Sector Update for 11/14/2019: HALO,AXNX,CGC", "HALO December 2020 Options Begin Trading", "Halozyme Therapeutics Inc (HALO) Q3 2019 Earnings Call Transcript", "HALO Makes Bullish Cross Above Critical Moving Average", "Halozyme Therapeutics Inc (HALO) Q4 2019 Earnings Call Transcript", "Health Care Sector Update for 11/04/2019: BNTX,WMGI,EPZM,HALO", "Notable Monday Option Activity: EOG, SSTK, HALO", "Health Care Sector Update for 11/04/2019: EPZM,WMGI,HALO,SYK", "Halozyme's Cancer Drug Fails To Meet Primary Endpoint; To Cut Jobs", "Halozyme Therapeutics (HALO) Shares Cross Below 200 DMA", "Halozyme: Genentech Reports Positive Outcome From Phase III Study Using ENHANZE", "Look Under The Hood: VB Has 16% Upside", "FDA Says \"Not Now AVEO\", HALO Axes 160 Jobs, RDHL Gets Nod For H.pylori Drug", "Health Care Sector Update for 11/04/2019: BNTX,WMGI,EPZM,HALO", "Notable Monday Option Activity: EOG, SSTK, HALO", "JKK's Holdings Imply 14% Gain Potential", "Interesting HALO Put And Call Options For August 16th", "HALO Makes Bullish Cross Above Critical Moving Average", "Notable Wednesday Option Activity: HALO, JNJ, C", "First Week of HALO December 20th Options Trading", "HALO Crosses Below Key Moving Average Level", "HALO Crosses Above Key Moving Average Level", "3 Cancer Treatment Stocks to Buy in March", "Interesting HALO Put And Call Options For May 17th", "Top Ranked Momentum Stocks to Buy for March 4th", "Halozyme Therapeutics Inc (HALO) Q4 2018 Earnings Conference Call Transcript", "Halozyme Therapeutics (HALO) Reports Q4 Loss, Tops Revenue Estimates", "Analysts Estimate Halozyme Therapeutics (HALO) to Report a Decline in Earnings: What to Look Out for", "HALO Crosses Above Key Moving Average Level", "Alexion's (ALXN) Earnings Beat Estimates in Q4, Shares Up", "Alexion (ALXN) to Report Q4 Earnings: What's in the Cards?", "Alexion's Ultomiris Meets Primary Endpoint in aHUS Study", "Noteworthy Thursday Option Activity: CSX, HALO, QCOM", "Health Care Sector Update for 01/10/2019: AMRN,PFE,HALO,PRPO,CGIX", "Health Care Sector Update for 01/10/2019: HALO,PRPO,CGIX", "Alexion's (ALXN) Soliris Drives Growth Amid Pricing Pressure", "Notable Tuesday Option Activity: ANET, HALO, SXC", "Health Care Sector Update for 11/27/2018: HALO,GTHX,ACAD", "Health Care Sector Update for 11/27/2018: VRTX,HALO,GTHX,ACAD", "Halozyme Therapeutics Sees Hammer Chart Pattern: Time to Buy?", "Halozyme Therapeutics (HALO) Reports Q3 Loss, Misses Revenue Estimates", "Halozyme Therapeutics Becomes Oversold (HALO)", "Alexion's (ALXN) Earnings Beat Estimates in Q2, Guidance Up", "HALO Makes Notable Cross Below Critical Moving Average", "Alexion's Ultomiris Gets Early FDA Nod for Rare Blood Disorder", "Earnings Reaction History: Halozyme Therapeutics Inc., 33.3% Follow-Through Indicator, 4.5% Sensitive", "Options Traders Expect Huge Moves in Halozyme Therapeutics (HALO) Stock", "This News Explains Halozyme Therapeutics' Double-Digit Drop Today", "Stocks To Watch: Halozyme Therapeutics Sees RS Rating Rise To 92", "Better Buy for 2018: Cara Therapeutics or Nektar Therapeutics?", "3 Top Stocks Wall Street Is Overlooking", "Noteworthy Tuesday Option Activity: HALO, SWKS, MTDR", "Alexion-Complement Pharma Tie Up to Treat Neuro Disorders", "Earnings Reaction History: Halozyme Therapeutics Inc., 33.3% Follow-Through Indicator, 4.5% Sensitive", "The Zacks Analyst Blog Highlights: Halozyme Therapeutics, Protagonist Therapeutics, Aptose Biosciences and Pieris Pharmaceuticals", "Why Halozyme Therapeutics (HALO) Could Be Positioned for a Surge", "Bristol-Myers' Opdivo/Yervoy sBLA for RCC Accepted by FDA", "4 Top-Ranked Biotech Stocks Under $20 With Room for Growth", "Halozyme Therapeutics Reaches Analyst Target Price", "Bristol-Myers (BMY) Reports Positive Data on Leukemia Drug", "Roche Buys Cancer Drug Maker Ignyta In A $1.7 Billion Deal", "Why This Biotech Could See 30% Upside In The Second Quarter", "Health Care Sector Update for 12/07/2017: MYO, ENTL, SYK, ALXN, HALO", "Health Care Sector Update for 12/07/2017: SCMP,ENTL,SYK,ALXN", "Implied Volatility Surging for Halozyme Therapeutics (HALO) Stock Options", "Why Halozyme Therapeutics, Inc. Deserves Its 52-Week High", "Third Security, LLC Buys Precipio Inc", "Should You Buy Halozyme Therapeutics (HALO) Ahead of Earnings?", "Options Traders Expect Huge Moves in Halozyme Therapeutics (HALO) Stock", "3 Drug Stocks Hitting 52-Week Highs: Are They Buys?", "3 Monster Stocks in the Making", "Tax Rate Down, Market Up", "Can Halozyme (HALO) Run Higher on Strong Earnings Estimate Revisions?", "Biotech Stock Roundup: FDA Nod for First Cancer Biosimilar, HALO up on Deals, Raised Outlook", "Halozyme, Inovalon, and Teva Soared This Week: Can They Go Higher?", "Bristol-Myers (BMY) Collaborates With Halozyme for ENHANZE", "Commit To Buy Halozyme Therapeutics At $12, Earn 7.9% Using Options", "3 Drug Stocks Hitting 52-Week Highs: Are They Buys?", "3 Monster Stocks in the Making", "Notable Thursday Option Activity: SN, HALO, TMUS", "Mid-Morning Market Update: Markets Mostly Lower; United Natural Foods Profit Beats Expectations", "Health Care Sector Update for 09/14/2017: HALO", "Futures Pull-Back as Inflation Perks Up, Chinese Economy Slows", "Strength Seen in Halozyme Therapeutics (HALO): Stock Soars 21.2%", "Halozyme Up After Cancer Deal, Markets Down", "Why Halozyme Therapeutics, Tenet Healthcare, and AMC Entertainment Holdings Jumped Today", "Mid-Afternoon Market Update: Dow Gains 50 Points; Glaukos Shares Slide", "Analysts Forecast 10% Gains Ahead For VXF", "Roche's (RHHBY) Combination Cancer Remedy Wins FDA Approval", "Notable Friday Option Activity: FINL, X, HALO", "Why Halozyme Therapeutics Inc. Sank 16.5% in May", "Pre-Market Most Active for Sep 14, 2017 : FDC, HALO, GM, BTI, SMFG, THC, TVIX, BAC, QQQ, USLV, BLDP, AAPL", "Mid-Morning Market Update: Markets Open Higher; Deere Earnings Beat Views", "Pre-Market Most Active for May 19, 2017 : PTXP, DYN, RDS/B, FWONK, QQQ, PBR, SBGL, BAC, XIV, NTEST, HALO, GLYC", "Why Halozyme Therapeutics, Seadrill, and Sibanye Gold Slumped Today", "Halozyme Therapeutics, Inc.'s Necessary Move Sends Shares Down as Much as 10%", "Mid-Afternoon Market Update: Dow Climbs 150 Points; Foot Locker Shares Drop On Earnings Miss", "Friday's ETF Movers: ILF, XBI", "Thursday's ETF Movers: KRE, XBI", "Mid-Day Market Update: Crude Oil Up 2%; Halozyme Therapeutics Shares Plunge", "Here's Why Halozyme Therapeutics, Inc Is Falling", "Commit To Purchase Halozyme Therapeutics At $8, Earn 9.4% Using Options", "10 Small-Cap Stocks That Could Double in the Next 3 Months", "Notable Thursday Option Activity: HALO, TIF, WDC", "5 Small-Cap Biotech Stocks to Buy in March", "Why Halozyme Therapeutics (HALO) Might Surprise This Earnings Season", "Noteworthy Tuesday Option Activity: PANW, YELP, HALO", "Thursday Sector Laggards: Drugs, Biotechnology Stocks", "5 Small-Cap Biotech Stocks to Buy in February", "Nektar Therapeutics: An Undervalued Biopharmaceuticals Company With Plenty In The Pipeline", "Halozyme Therapeutics Reaches Analyst Target Price", "Halozyme Therapeutics (HALO) in Focus: Stock Up 6.4%", "Here's Why Halozyme Therapeutics Fell as Much as 11.1% Today", "Can the Rally in Halozyme (HALO) Shares Continue?", "Why Halozyme Therapeutics, Inc Fell 40.6% in 2016", "Why Halozyme Therapeutics, Inc. Jumped 15.6% in January", "Halozyme (HALO) Up on Positive Phase II Data on PEGPH20", "Why Halozyme Therapeutics, Inc Is Rising Today", "Wall Street Tips Lower; Jobless Claims Fall More Than Expected", "Pre-Market Most Active for Jan 5, 2017 : HALO, HLX, ICL, JCP, SIRI, M, BAC, KSS, NVDA, MYL, TVIX, GNCA", "US Futures Nudge Lower Ahead of Jobs, Services Data", "Why Barrick Gold, Halozyme Therapeutics, and CEB Jumped Today", "HALO Crosses Below Key Moving Average Level", "Halozyme Therapeutics (HALO) Worth a Look: Stock Up 18%", "Halozyme (HALO) Up on Positive Phase II Data on PEGPH20", "Why Halozyme Therapeutics, Inc Is Rising Today", "Why Halozyme Therapeutics, Inc. Stock Jumped 21.2% in September", "Stocks Rebound on Deutsche Bank Rumors", "Halozyme Therapeutics, Inc. (HALO) Keeping Good Company", "Halozyme Therapeutics (HALO) Catches Eye: Stock Up 7.9%", "Noteworthy Friday Option Activity: JBL, HALO, CALX", "Here's Why These Biopharma Stocks Soared at Least 10% Today", "Mid-Morning Market Update: Markets Open Higher; Devon Energy To Sell Non-Core Upstream Assets For Around $1 Billion", "The Zacks Analyst Blog Highlights: Horizon Pharma, Incyte, Juno Therapeutics, Halozyme Therapeutics and Kite Pharma", "Earnings Reaction History: Halozyme Therapeutics Inc., 42.9% Follow-Through Indicator, 5.6% Sensitive", "Noteworthy Tuesday Option Activity: WETF, HALO, PPC", "Trade of the Day: Halozyme Therapeutics, Inc. (NASDAQ:HALO)", "3 Small-Cap Stocks to Buy in September", "Earnings Reaction History: Halozyme Therapeutics Inc., 50.0% Follow-Through Indicator, 11.9% Sensitive", "Halozyme Therapeutics is Now Oversold", "Why Halozyme Therapeutics Inc Plunged 51% in January", "How The Pieces Add Up: IYH Targets $175", "The 1 Thing I Wish Someone Had Told Me When I First Started Investing", "Halozyme Gets $5M as AbbVie Begins Dosing in Humira Trial", "Halozyme Therapeutics (HALO) in Focus: Stock Rises 6.7%", "Health Care Sector Update for 03/01/2016: HALO, NSTG, RMTI", "Earnings Reaction History: Halozyme Therapeutics Inc., 50.0% Follow-Through Indicator, 11.9% Sensitive", "Mid-Afternoon Market Update: Dow Tumbles Over 300 Points; Cyberark Shares Gain Following Merger Chatter", "Halozyme Therapeutics (HALO) in Focus: Stock Tumbles 16.7%", "Halozyme Therapeutics is Now Oversold (HALO)", "Health Care Sector Update for 01/11/2016: OREX, HALO", "Why Halozyme Therapeutics Inc. Rose 76% in 2015", "Halozyme Raises Funds to Support Ongoing Oncology Studies", "Mid-Morning Market Update: Markets Down; JPMorgan Beats Q4 Expectations", "Wednesday's ETF Movers: NANR, XBI", "HALO January 2018 Options Begin Trading", "Earnings Reaction History: Halozyme Therapeutics Inc., 40.0% Follow-Through Indicator, 12.9% Sensitive", "Why Halozyme Therapeutics Inc Is Heading Lower Today", "Bullish Two Hundred Day Moving Average Cross - HALO", "3 Biotechs That Play Well with Others", "Halozyme Inks Collaboration Deal with Eli Lilly for Enhanze", "Why Halozyme Therapeutics Inc. Jumped 13% in November", "Halozyme Therapeutics Inc Rose 14% in October -- Here's Why", "Oversold Conditions For Halozyme Therapeutics (HALO)", "Why Halozyme Shares Jumped 10% Today", "After-Hours Earnings Report for August 10, 2015 : BAP, IFF, VIPS, XON, FNV, RAX, SF, PRAA, KITE, NVAX, HALO, TTWO", "First Week of March 2016 Options Trading For Halozyme Therapeutics (HALO)", "Can The Uptrend Continue for Halozyme Therapeutics (HALO)? - Tale of the Tape", "Why Shares of Halozyme Therapeutics Inc. Plunged 24% in August", "Halozyme-AbbVie Ink Deal for ENHANZE Platform, Shares Up - Analyst Blog", "Why Shares in Halozyme Therapeutics, Inc. Are Soaring Higher", "Halozyme to Advance PEGPH20 Following FDA Meet - Analyst Blog", "Commit To Buy Halozyme Therapeutics At $10, Earn 15.5% Using Options", "How one bull is playing Halozyme", "Halozyme Q4 Loss Narrower-than-Expected, Revenues Up - Analyst Blog", "After-Hours Earnings Report for March 2, 2015 : PANW, SLXP, XON, GWRE, PRAA, ALEX, HALO, MTDR, CZR, NTK, INN, HTGC", "Can Halozyme Therapeutics (HALO) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape", "Health Care Sector Update for 12/24/2014: HALO, BDSI, ENDP", "HALO Crosses Above Key Moving Average Level", "Halozyme Up on Collaboration and Licensing Deal with J&J - Analyst Blog", "Can Pfizer\u2019s Cholesterol Drug Catch Up To The Competition?", "First Week of HALO June 2015 Options Trading", "Actelion Misses Q3 Earnings Expectation, Ups 2014 Guidance - Analyst Blog", "Vertex Pharmaceuticals' Kalydeco Wins FDA Panel Backing - Analyst Blog", "XBI, FMI, EXEL, HALO: Large Inflows Detected at ETF", "NewLink-Roche Ink Deal for Oncology Candidate Development - Analyst Blog", "Regeneron Pharmaceuticals (REGN) Jumps: Stock Up 8.5% - Tale of the Tape", "Amicus Reports Additional Positive Data on Fabry Therapy - Analyst Blog", "Novavax (NVAX) Moves Up: Stock Adds 10.1% in Session - Tale of the Tape", "What Falling Estimates & Price Mean for Enzo Biochem (ENZ) - Tale of the Tape", "Lexicon Pharmaceuticals (LXRX) Jumps: Stock Rises 15.7% - Tale of the Tape", "Ultragenyx Reports Data from Sialic Acid Deficiency Study - Analyst Blog", "Biogen's Q3 Earnings Top Estimates, View Raised Again - Analyst Blog", "Peregrine Pharmaceuticals (PPHM) Jumps: Stock Rises 10.7% - Tale of the Tape", "NewLink Genetics (NLNK) Shows Strength: Stock Up 23.7% - Tale of the Tape", "Prosensa Holding N.V. (RNA) in Focus: Stock up 8.5% - Tale of the Tape", "Halozyme's PEGPH20 Receives FDA Orphan Drug Designation - Analyst Blog", "Halozyme's PEGPH20 Study S1313 Clinical Hold Lifted by FDA - Analyst Blog", "Halozyme Therapeutics (HALO) Jumps: Stock Up 9.3% - Tale of the Tape", "Baxter and Halozyme Therapeutics Get FDA Approval - Analyst Blog", "MannKind (MNKD) Worth Watching: Stock Gains 12.9% - Tale of the Tape", "Peregrine Pharmaceuticals (PPHM) Jumps: Stock Rises 10.7% - Tale of the Tape", "Why You Shouldn't Bet Against Halozyme Therapeutics (HALO) Stock - Tale of the Tape", "Halozyme's PEGPH20 Program Gains Fast Track Designation - Analyst Blog", "Halozyme Gains on Narrower-than-Expected Loss, Revenues Up - Analyst Blog", "Earnings Reaction History: Halozyme Therapeutics Inc., 33.3% Follow-Through Indicator, 15.0% Sensitive", "Biotech Stock Roundup: Biogen Hemophilia Drug Approved, Ariad & Halozyme Clinical Hold Lifted - Analyst Blog", "Pre-Market Most Active for Jun 5, 2014 : RAD, S, RCAP, AUY, ALU, CIEN, QQQ, XIV, HALO, FB, ZNGA, MRVL", "Sector Update: Health Care Stocks Mixed; Baxter International, Halo Therapeutics Declining Despite Regulatory OKs for Hemophilia Drug", "Sector Update: Healthcare Healthcare", "Halozyme Study Clinical Hold Lifted by FDA - Analyst Blog", "Mid-Day Market Update: US Stocks Surge; PVH Shares Slip On Downbeat Results", "Thursday's ETF Movers: XBI, EWD", "After Hours Most Active for Jun 4, 2014 : WY, ALLY, WFM, FRX, XOM, RF, PL, INTC, CMCSA, MSFT, QQQ, HALO", "Halozyme Therapeutics, Inc. (HALO) in Focus: Stock Up 6.9% - Tale of the Tape", "Mid-Day Market Update: Rackspace Gains On Upbeat Earnings; DXP Enterprises Shares Slip", "Sector Update: Technology Shares Flat Pre-Market; Clovis Oncology Upgraded to Buy at Stifel Nicolaus", "Mid-Morning Market Update: Markets Gain; Elizabeth Arden To Explore Strategic Alternatives", "Pre-Market Most Active for May 13, 2014 : ALU, NRF, ING, OKS, FB, DTV, BAC, HSBC, QQQ, FCEL, HALO, GMCR", "Mid-Afternoon Market Update: Markets Trade In Choppy Session As Elizabeth Arden Shares Remain Down", "Mid-Morning Market Update: Markets Gain; Johnson & Johnson Profit Beats Street View", "Healthcare Stocks Declining Again; Halozyme Giving Back Early Gains Linked to Citigroup 'Buy' Rating", "Sector Update: Healthcare", "Halozyme Study Under Clinical Hold - Analyst Blog", "Halozyme's Q1 Loss Widens - Analyst Blog", "Sector Update: Health-Care Shares Higher Pre-Market; Intuitive Surgical Up 9% on Q1 Guidance", "Pre-Market Most Active for Apr 9, 2014 : NOK, FB, SIRI, AA, VZ, QQQ, SNY, BAC, GM, HALO, VOD, FCEL", "Halozyme Falls on Phase II Study Halt - Analyst Blog", "Mid-Day Market Update: NASDAQ Tumbles 1.8%; SYNNEX Shares Gain After Upbeat Results", "Mid-Morning Market Update: Markets Mixed; CarMax Results Miss Estimates", "US Stocks Poised For Higher Close This Week; Mylan Reportedly Eyes Swedish Rival", "Stock Futures Edge Higher Even as Payroll Growth Slows, Jobless Rate Flat at 6.7%", "Sector Update: Healthcare", "Friday's ETF Movers: GDXJ, XBI", "Mid-Afternoon Market Update: Markets Drop, Lead Lower by NASDAQ Momentum Names", "EC Approves Roche/Halozyme's MabThera SC - Analyst Blog", "Mid-Morning Market Update: Markets Open Higher; UTi Worldwide Reports Q4 Loss", "Notable Two Hundred Day Moving Average Cross - HALO", "Positive Data on Halozyme Candidate - Analyst Blog", "Cara Therapeutics (CARA) Zooms: Stock Up 12.4% - Tale of the Tape", "Pre-Market Most Active for Apr 4, 2014 : MU, BAC, QQQ, SEAS, HALO, WMC, FB, VOD, MYL, ALU, APC, BBL", "Mid-Afternoon Market Update: Markets Take a Sharp Dip to the Downside, as Traders Take Month-End Profits", "Halozyme's Q4 Loss Wider-Than-Expected - Analyst Blog", "After Hours Most Active for Feb 19, 2014 : BAC, QQQ, C, TSLA, CIG, PBR/A, PBR, SWY, MU, WEN, FB, HALO", "Pre-Market Most Active for Feb 5, 2014 : NOK, HALO, BAC, SAN, JCP, XIV, LPL, TVIX, QQQ, VALE, FB, INTC", "Good News for Halozyme - Analyst Blog", "Pipeline Updates from Halozyme Therapeutics - Analyst Blog", "Halozyme Therapeutics (HALO) Jumps: Stock Up 16.6% - Tale of the Tape", "bluebird bio (BLUE) Zooms: Stock Up 7.2% - Tale of the Tape", "Largest option trades in equities", "Sector Update: Healthcare Shares Mixed; Halozyme Surges 10% on Q3 Results", "Sector Update: Healthcare", "ViroPharma Beats by a Penny - Analyst Blog", "Is This the Top for Halozyme Therapeutics, Inc. (HALO) - Tale of the Tape", "Halozyme (HALO) in Focus: Stock Rises 6.9% - Analyst Blog", "Sector Update: Healthcare Shares Down Pre-Market; Nektar Loses 22% After Phase 2 Study Results", "Bulls make fast money in Halozyme", "Insiders Buy at Aircastle and Halozyme While Orbitz Worldwide Sees a Major Sale", "Loss Widens at Halozyme in Q2 - Analyst Blog", "VPHM Misses on Earnings & Revs - Analyst Blog", "Pre-Market Most Active for Aug 1, 2013 : DELL, JCP, BAC, SUNE, FB, ALU, SXC, BCRX, XOM, ARNA, MYL, HALO", "Benzinga Market Wrap for Thursday, August 1: Record Highs!", "Halozyme Therapeutics, Inc. Bulls See Lofty Gains Ahead", "Mid-Afternoon Market Update: Optimer Falls as Halozyme Rockets Upwards", "Sector Update: Healthcare", "ViroPharma Reports Loss in 1Q - Analyst Blog", "Market Wrap for Friday, March 22: Stocks Rise on Hopes of Bailout Deal for Cyprus", "Mid-Day Market Update: Micron Surges On Upbeat Revenue, Informatica Declines", "ViroPharma Tops on All Fronts - Analyst Blog", "Largest option buying in equities so far", "One Biotech Stock Investors are Unfairly Ignoring", "Upbeat 2013 from ViroPharma - Analyst Blog", "Mid-Day Market Update: US Stocks Fluctuate, Cisco Systems Up on Better-than-Expected Earnings", "ViroPharma Reports Loss in 1Q - Analyst Blog", "ViroPharma Presents Cinryze Data - Analyst Blog", "Revenues Fall at ViroPharma - Analyst Blog", "Pertaining to Relief for ViroPharma - Analyst Blog", "ViroPharma Misses Zacks Estimates - Analyst Blog", "VPHM Manufacturing Process Approved - Analyst Blog", "Pfizer Signs a Couple of Deals - Analyst Blog", "Pre-Market Most Active for Dec 21, 2012 : BAC, RIMM, ITUB, QQQ, NOK, TOT, SIRI, C, FB, NJ, HALO, ASCA", "Mid-Afternoon Update: Herbalife Takes a Bigger Beating, Markets Still Red", "ViroPharma Presents Cinryze Data - Analyst Blog", "Revenues Fall at ViroPharma - Analyst Blog", "VPHM-HALO Report Encouraging Data - Analyst Blog", "ViroPharma's Cinryze Reaches UK - Analyst Blog", "ViroPharma Beats; All Set to Shine - Analyst Blog", "Bad News for ViroPharma - Analyst Blog", "Top Stocks with Big Potential Catch-Up Moves - Screen of the Week", "Zacks.com featured expert Kevin Matras highlights: Brookfield Office Properties Inc., Fiserv, Inc., Halozyme Therapeutics, Inc., Jacobs Engineering Group Inc. and MarketAxess Holdings Inc. - Press Releases", "Priority Review for VPHM's Drug - Analyst Blog", "ViroPharma's Seizure Drug Reaches UK - Analyst Blog", "ViroPharma-Halozyme Drug Advances - Analyst Blog", "Value Ideas: Top 10 Options Market Picks Trading Well Below Target Price", "The Top 20 Most Undervalued Healthcare Stocks By Target Price", "Update on VPHM's Industrial Facility - Analyst Blog", "Tuesday Losers: Anadarko, Regal Cinemas and Halozyme"], "Elapsed Time": ["MAY 12, 2020", "APR 27, 2020", "APR 27, 2020", "MAR 27, 2020", "MAR 24, 2020", "MAR 13, 2020", "MAR 12, 2020", "MAR 2, 2020", "MAY 12, 2020", "JAN 23, 2020", "NOV 15, 2019", "NOV 14, 2019", "NOV 14, 2019", "NOV 14, 2019", "NOV 12, 2019", "NOV 5, 2019", "FEB 24, 2020", "NOV 4, 2019", "NOV 4, 2019", "NOV 4, 2019", "NOV 4, 2019", "SEP 24, 2019", "SEP 13, 2019", "SEP 5, 2019", "NOV 5, 2019", "NOV 4, 2019", "JUL 23, 2019", "JUL 3, 2019", "JUN 26, 2019", "JUN 17, 2019", "JUN 12, 2019", "APR 29, 2019", "SEP 3, 2019", "APR 2, 2019", "MAR 23, 2019", "MAR 19, 2019", "MAR 4, 2019", "FEB 21, 2019", "FEB 21, 2019", "FEB 14, 2019", "APR 2, 2019", "FEB 4, 2019", "JAN 31, 2019", "JAN 29, 2019", "JAN 17, 2019", "JAN 10, 2019", "JAN 10, 2019", "DEC 27, 2018", "FEB 5, 2019", "NOV 27, 2018", "NOV 27, 2018", "NOV 14, 2018", "NOV 6, 2018", "OCT 24, 2018", "JUL 26, 2018", "JUN 21, 2018", "DEC 24, 2018", "MAY 10, 2018", "FEB 15, 2018", "JAN 17, 2018", "JAN 11, 2018", "JAN 6, 2018", "DEC 26, 2017", "DEC 26, 2017", "JUN 12, 2018", "MAY 10, 2018", "DEC 15, 2017", "DEC 15, 2017", "DEC 15, 2017", "DEC 14, 2017", "DEC 14, 2017", "DEC 12, 2017", "DEC 22, 2017", "DEC 8, 2017", "DEC 7, 2017", "DEC 7, 2017", "NOV 20, 2017", "NOV 8, 2017", "NOV 7, 2017", "NOV 3, 2017", "DEC 11, 2017", "OCT 17, 2017", "OCT 10, 2017", "SEP 28, 2017", "SEP 22, 2017", "SEP 20, 2017", "SEP 16, 2017", "SEP 15, 2017", "OCT 25, 2017", "OCT 17, 2017", "OCT 10, 2017", "SEP 14, 2017", "SEP 14, 2017", "SEP 14, 2017", "SEP 14, 2017", "SEP 15, 2017", "SEP 14, 2017", "SEP 14, 2017", "SEP 14, 2017", "AUG 14, 2017", "JUN 26, 2017", "JUN 16, 2017", "JUN 6, 2017", "SEP 14, 2017", "MAY 19, 2017", "MAY 19, 2017", "MAY 19, 2017", "MAY 19, 2017", "MAY 19, 2017", "MAY 19, 2017", "MAR 30, 2017", "MAY 19, 2017", "MAR 30, 2017", "MAR 21, 2017", "MAR 21, 2017", "MAR 16, 2017", "MAR 2, 2017", "FEB 27, 2017", "FEB 14, 2017", "MAR 30, 2017", "JAN 25, 2017", "JAN 20, 2017", "JAN 10, 2017", "JAN 10, 2017", "JAN 10, 2017", "JAN 9, 2017", "JAN 6, 2017", "FEB 2, 2017", "JAN 6, 2017", "JAN 5, 2017", "JAN 5, 2017", "JAN 5, 2017", "JAN 5, 2017", "JAN 5, 2017", "DEC 22, 2016", "JAN 6, 2017", "JAN 6, 2017", "JAN 5, 2017", "OCT 10, 2016", "SEP 30, 2016", "SEP 30, 2016", "SEP 19, 2016", "DEC 16, 2016", "NOV 9, 2016", "JUN 6, 2016", "MAY 9, 2016", "MAY 9, 2016", "APR 19, 2016", "APR 18, 2016", "AUG 31, 2016", "FEB 29, 2016", "FEB 18, 2016", "FEB 6, 2016", "FEB 4, 2016", "JAN 24, 2016", "JAN 22, 2016", "JAN 21, 2016", "MAR 1, 2016", "JAN 13, 2016", "JAN 13, 2016", "JAN 12, 2016", "JAN 11, 2016", "JAN 11, 2016", "JAN 9, 2016", "JAN 5, 2016", "JAN 14, 2016", "JAN 13, 2016", "NOV 16, 2015", "NOV 10, 2015", "NOV 10, 2015", "NOV 4, 2015", "OCT 1, 2015", "DEC 22, 2015", "DEC 5, 2015", "NOV 18, 2015", "AUG 20, 2015", "AUG 11, 2015", "AUG 10, 2015", "JUL 21, 2015", "JUL 15, 2015", "SEP 12, 2015", "JUN 4, 2015", "JUN 1, 2015", "APR 9, 2015", "MAR 31, 2015", "MAR 18, 2015", "MAR 3, 2015", "MAR 2, 2015", "JUN 11, 2015", "DEC 24, 2014", "DEC 19, 2014", "DEC 18, 2014", "DEC 11, 2014", "OCT 27, 2014", "OCT 22, 2014", "OCT 22, 2014", "FEB 27, 2015", "OCT 21, 2014", "OCT 20, 2014", "OCT 20, 2014", "OCT 17, 2014", "OCT 17, 2014", "OCT 17, 2014", "OCT 17, 2014", "OCT 22, 2014", "OCT 16, 2014", "OCT 14, 2014", "OCT 14, 2014", "OCT 7, 2014", "SEP 19, 2014", "SEP 18, 2014", "SEP 15, 2014", "OCT 16, 2014", "OCT 16, 2014", "SEP 8, 2014", "SEP 5, 2014", "AUG 14, 2014", "AUG 11, 2014", "JUN 11, 2014", "JUN 5, 2014", "SEP 15, 2014", "JUN 5, 2014", "JUN 5, 2014", "JUN 5, 2014", "JUN 5, 2014", "JUN 4, 2014", "MAY 14, 2014", "MAY 13, 2014", "JUN 5, 2014", "MAY 13, 2014", "MAY 13, 2014", "MAY 13, 2014", "APR 15, 2014", "APR 15, 2014", "APR 15, 2014", "APR 10, 2014", "MAY 13, 2014", "APR 9, 2014", "APR 9, 2014", "APR 8, 2014", "APR 4, 2014", "APR 4, 2014", "APR 4, 2014", "APR 4, 2014", "APR 9, 2014", "APR 4, 2014", "APR 4, 2014", "MAR 31, 2014", "MAR 31, 2014", "MAR 27, 2014", "MAR 26, 2014", "FEB 28, 2014", "APR 4, 2014", "FEB 28, 2014", "FEB 28, 2014", "FEB 19, 2014", "FEB 5, 2014", "JAN 27, 2014", "JAN 14, 2014", "DEC 19, 2013", "FEB 28, 2014", "DEC 18, 2013", "NOV 8, 2013", "NOV 8, 2013", "NOV 1, 2013", "OCT 3, 2013", "SEP 30, 2013", "SEP 27, 2013", "DEC 19, 2013", "AUG 15, 2013", "AUG 8, 2013", "AUG 2, 2013", "AUG 1, 2013", "AUG 1, 2013", "JUN 25, 2013", "MAY 16, 2013", "SEP 27, 2013", "MAY 2, 2013", "MAR 22, 2013", "MAR 22, 2013", "FEB 28, 2013", "JAN 30, 2013", "JAN 15, 2013", "JAN 8, 2013", "MAY 16, 2013", "MAY 2, 2013", "NOV 14, 2012", "OCT 29, 2012", "SEP 25, 2012", "AUG 10, 2012", "AUG 7, 2012", "DEC 26, 2012", "DEC 21, 2012", "DEC 21, 2012", "NOV 14, 2012", "APR 17, 2012", "MAR 19, 2012", "MAR 12, 2012", "MAR 2, 2012", "AUG 3, 2012", "JAN 17, 2012", "JAN 17, 2012", "JAN 16, 2012", "DEC 14, 2011", "DEC 7, 2011", "NOV 15, 2011", "JAN 14, 2011", "FEB 9, 2012", "JUN 1, 2010"], "Published Date": [], "Link": ["https://www.nasdaq.com/articles/halozyme-therapeutics-inc-halo-q1-2020-earnings-call-transcript-2020-05-12", "https://www.nasdaq.com/articles/biotech-stocks-facing-fda-decision-in-may-2020-2020-04-27", "https://www.nasdaq.com/articles/halo-crosses-above-average-analyst-target-2020-04-27", "https://www.nasdaq.com/articles/first-week-of-may-15th-options-trading-for-halozyme-therapeutics-halo-2020-03-27", "https://www.nasdaq.com/articles/tuesday-3-24-insider-buying-report%3A-halo-afl-2020-03-24", "https://www.nasdaq.com/articles/halozyme-therapeutics-is-now-oversold-halo-2020-03-13", "https://www.nasdaq.com/articles/halo-makes-notable-cross-below-critical-moving-average-2020-03-12", "https://www.nasdaq.com/articles/can-halozyme-therapeutics-continue-its-momentum-in-2020-2020-03-02", "https://www.nasdaq.com/articles/halozyme-therapeutics-inc-halo-q1-2020-earnings-call-transcript-2020-05-12", "https://www.nasdaq.com/articles/interesting-halo-put-and-call-options-for-september-18th-2020-01-23", "https://www.nasdaq.com/articles/halo-crosses-above-average-analyst-target-2019-11-15", "https://www.nasdaq.com/articles/health-care-sector-update-for-11-14-2019%3A-replhaloaxnxcgcweed.to-2019-11-14", "https://www.nasdaq.com/articles/health-care-sector-update-for-11-14-2019%3A-haloaxnxcgc-2019-11-14", "https://www.nasdaq.com/articles/halo-december-2020-options-begin-trading-2019-11-14", "https://www.nasdaq.com/articles/halozyme-therapeutics-inc-halo-q3-2019-earnings-call-transcript-2019-11-13", "https://www.nasdaq.com/articles/halo-makes-bullish-cross-above-critical-moving-average-2019-11-05", "https://www.nasdaq.com/articles/halozyme-therapeutics-inc-halo-q4-2019-earnings-call-transcript-2020-02-25", "https://www.nasdaq.com/articles/health-care-sector-update-for-11-04-2019%3A-bntxwmgiepzmhalo-2019-11-04", "https://www.nasdaq.com/articles/notable-monday-option-activity%3A-eog-sstk-halo-2019-11-04", "https://www.nasdaq.com/articles/health-care-sector-update-for-11-04-2019%3A-epzmwmgihalosyk-2019-11-04", "https://www.nasdaq.com/articles/halozymes-cancer-drug-fails-to-meet-primary-endpoint-to-cut-jobs-2019-11-04", "https://www.nasdaq.com/articles/halozyme-therapeutics-halo-shares-cross-below-200-dma-2019-09-24", "https://www.nasdaq.com/articles/halozyme%3A-genentech-reports-positive-outcome-from-phase-iii-study-using-enhanze-2019-09-13", "https://www.nasdaq.com/articles/look-under-the-hood%3A-vb-has-16-upside-2019-09-05", "https://www.nasdaq.com/articles/fda-says-not-now-aveo-halo-axes-160-jobs-rdhl-gets-nod-for-h.pylori-drug-2019-11-05", "https://www.nasdaq.com/articles/health-care-sector-update-for-11-04-2019%3A-bntxwmgiepzmhalo-2019-11-04", "https://www.nasdaq.com/articles/interesting-halo-put-and-call-options-for-march-2020-2019-07-23", "https://www.nasdaq.com/articles/jkks-holdings-imply-14-gain-potential-2019-07-03", "https://www.nasdaq.com/articles/interesting-halo-put-and-call-options-for-august-16th-2019-06-26", "https://www.nasdaq.com/articles/halo-makes-bullish-cross-above-critical-moving-average-2019-06-17", "https://www.nasdaq.com/articles/notable-wednesday-option-activity%3A-halo-jnj-c-2019-06-12", "https://www.nasdaq.com/articles/first-week-halo-december-20th-options-trading-2019-04-29", "https://www.nasdaq.com/articles/halo-crosses-below-key-moving-average-level-2019-09-03", "https://www.nasdaq.com/articles/halo-crosses-above-key-moving-average-level-2019-04-02-0", "https://www.nasdaq.com/articles/3-cancer-treatment-stocks-buy-march-2019-03-23", "https://www.nasdaq.com/articles/interesting-halo-put-and-call-options-may-17th-2019-03-19", "https://www.nasdaq.com/articles/top-ranked-momentum-stocks-to-buy-for-march-4th-2019-03-04", "https://www.nasdaq.com/articles/halozyme-therapeutics-inc-halo-q4-2018-earnings-conference-call-transcript-2019-02-21", "https://www.nasdaq.com/articles/halozyme-therapeutics-halo-reports-q4-loss-tops-revenue-estimates-2019-02-21", "https://www.nasdaq.com/articles/analysts-estimate-halozyme-therapeutics-halo-to-report-a-decline-in-earnings%3A-what-to-look", "https://www.nasdaq.com/articles/halo-crosses-above-key-moving-average-level-2019-04-02", "https://www.nasdaq.com/articles/alexions-alxn-earnings-beat-estimates-in-q4-shares-up-2019-02-04", "https://www.nasdaq.com/articles/alexion-alxn-to-report-q4-earnings%3A-whats-in-the-cards-2019-01-31", "https://www.nasdaq.com/articles/alexions-ultomiris-meets-primary-endpoint-in-ahus-study-2019-01-29", "https://www.nasdaq.com/articles/noteworthy-thursday-option-activity-csx-halo-qcom-2019-01-17", "https://www.nasdaq.com/articles/health-care-sector-update-01102019-amrnpfehaloprpocgix-2019-01-10", "https://www.nasdaq.com/articles/health-care-sector-update-01102019-haloprpocgix-2019-01-10", "https://www.nasdaq.com/articles/alexions-alxn-soliris-drives-growth-amid-pricing-pressure-2018-12-27", "https://www.nasdaq.com/articles/notable-tuesday-option-activity-anet-halo-sxc-2019-02-05", "https://www.nasdaq.com/articles/health-care-sector-update-11272018-halogthxacad-2018-11-27", "https://www.nasdaq.com/articles/health-care-sector-update-11272018-vrtxhalogthxacad-2018-11-27", "https://www.nasdaq.com/articles/halozyme-therapeutics-sees-hammer-chart-pattern%3A-time-to-buy-2018-11-14", "https://www.nasdaq.com/articles/halozyme-therapeutics-halo-reports-q3-loss-misses-revenue-estimates-2018-11-06", "https://www.nasdaq.com/articles/halozyme-therapeutics-becomes-oversold-halo-2018-10-24", "https://www.nasdaq.com/articles/alexions-alxn-earnings-beat-estimates-in-q2-guidance-up-2018-07-26", "https://www.nasdaq.com/articles/halo-makes-notable-cross-below-critical-moving-average-2018-06-21", "https://www.nasdaq.com/articles/alexions-ultomiris-gets-early-fda-nod-for-rare-blood-disorder-2018-12-24", "https://www.nasdaq.com/articles/earnings-reaction-history-halozyme-therapeutics-inc-333-follow-through-indicator-45", "https://www.nasdaq.com/articles/options-traders-expect-huge-moves-in-halozyme-therapeutics-halo-stock-2018-02-15", "https://www.nasdaq.com/articles/news-explains-halozyme-therapeutics-double-digit-drop-today-2018-01-17", "https://www.nasdaq.com/articles/stocks-watch-halozyme-therapeutics-sees-rs-rating-rise-92-2018-01-11", "https://www.nasdaq.com/articles/better-buy-2018-cara-therapeutics-or-nektar-therapeutics-2018-01-06", "https://www.nasdaq.com/articles/3-top-stocks-wall-street-overlooking-2017-12-26", "https://www.nasdaq.com/articles/noteworthy-tuesday-option-activity-halo-swks-mtdr-2017-12-26", "https://www.nasdaq.com/articles/alexion-complement-pharma-tie-up-to-treat-neuro-disorders-2018-06-12", "https://www.nasdaq.com/articles/earnings-reaction-history-halozyme-therapeutics-inc-333-follow-through-indicator-45", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-halozyme-therapeutics-protagonist-therapeutics-aptose", "https://www.nasdaq.com/articles/why-halozyme-therapeutics-halo-could-be-positioned-for-a-surge-2017-12-15", "https://www.nasdaq.com/articles/bristol-myers-opdivo-yervoy-sbla-for-rcc-accepted-by-fda-2017-12-15", "https://www.nasdaq.com/articles/4-top-ranked-biotech-stocks-under-%2420-with-room-for-growth-2017-12-14", "https://www.nasdaq.com/articles/halozyme-therapeutics-reaches-analyst-target-price-2017-12-14", "https://www.nasdaq.com/articles/bristol-myers-bmy-reports-positive-data-on-leukemia-drug-2017-12-12", "https://www.nasdaq.com/articles/roche-buys-cancer-drug-maker-ignyta-17-billion-deal-2017-12-22", "https://www.nasdaq.com/articles/why-biotech-could-see-30-upside-second-quarter-2017-12-08", "https://www.nasdaq.com/articles/health-care-sector-update-12072017-myo-entl-syk-alxn-halo-2017-12-07", "https://www.nasdaq.com/articles/health-care-sector-update-12072017-scmpentlsykalxn-2017-12-07", "https://www.nasdaq.com/articles/implied-volatility-surging-for-halozyme-therapeutics-halo-stock-options-2017-11-20", "https://www.nasdaq.com/articles/why-halozyme-therapeutics-inc-deserves-its-52-week-high-2017-11-08", "https://www.nasdaq.com/articles/third-security-llc-buys-precipio-inc-2017-11-07", "https://www.nasdaq.com/articles/should-you-buy-halozyme-therapeutics-halo-ahead-of-earnings-2017-11-03", "https://www.nasdaq.com/articles/options-traders-expect-huge-moves-in-halozyme-therapeutics-halo-stock-2017-12-11", "https://www.nasdaq.com/articles/3-drug-stocks-hitting-52-week-highs-are-they-buys-2017-10-17", "https://www.nasdaq.com/articles/3-monster-stocks-making-2017-10-10", "https://www.nasdaq.com/articles/tax-rate-down-market-2017-09-28", "https://www.nasdaq.com/articles/can-halozyme-halo-run-higher-on-strong-earnings-estimate-revisions-2017-09-22", "https://www.nasdaq.com/articles/biotech-stock-roundup-fda-nod-first-cancer-biosimilar-halo-deals-raised-outlook-2017-09-20", "https://www.nasdaq.com/articles/halozyme-inovalon-and-teva-soared-week-can-they-go-higher-2017-09-16", "https://www.nasdaq.com/articles/bristol-myers-bmy-collaborates-with-halozyme-for-enhanze-2017-09-15", "https://www.nasdaq.com/articles/commit-buy-halozyme-therapeutics-12-earn-79-using-options-2017-10-25", "https://www.nasdaq.com/articles/3-drug-stocks-hitting-52-week-highs-are-they-buys-2017-10-17", "https://www.nasdaq.com/articles/3-monster-stocks-making-2017-10-10", "https://www.nasdaq.com/articles/notable-thursday-option-activity-sn-halo-tmus-2017-09-14", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-mostly-lower-united-natural-foods-profit-beats", "https://www.nasdaq.com/articles/health-care-sector-update-09142017-halo-2017-09-14", "https://www.nasdaq.com/articles/futures-pull-back-inflation-perks-chinese-economy-slows-2017-09-14", "https://www.nasdaq.com/articles/strength-seen-in-halozyme-therapeutics-halo%3A-stock-soars-21.2-2017-09-15", "https://www.nasdaq.com/articles/halozyme-after-cancer-deal-markets-down-2017-09-14", "https://www.nasdaq.com/articles/why-halozyme-therapeutics-tenet-healthcare-and-amc-entertainment-holdings-jumped-today", "https://www.nasdaq.com/articles/mid-afternoon-market-update-dow-gains-50-points-glaukos-shares-slide-2017-09-14", "https://www.nasdaq.com/articles/analysts-forecast-10-gains-ahead-vxf-2017-08-14", "https://www.nasdaq.com/articles/roches-rhhby-combination-cancer-remedy-wins-fda-approval-2017-06-26", "https://www.nasdaq.com/articles/notable-friday-option-activity-finl-x-halo-2017-06-16", "https://www.nasdaq.com/articles/why-halozyme-therapeutics-inc-sank-165-may-2017-06-06", "https://www.nasdaq.com/articles/pre-market-most-active-sep-14-2017-fdc-halo-gm-bti-smfg-thc-tvix-bac-qqq-uslv-bldp-aapl", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-higher-deere-earnings-beat-views-2017-05-19", "https://www.nasdaq.com/articles/pre-market-most-active-may-19-2017-ptxp-dyn-rdsb-fwonk-qqq-pbr-sbgl-bac-xiv-ntest-halo", "https://www.nasdaq.com/articles/why-halozyme-therapeutics-seadrill-and-sibanye-gold-slumped-today-2017-05-19", "https://www.nasdaq.com/articles/halozyme-therapeutics-incs-necessary-move-sends-shares-down-much-10-2017-05-19", "https://www.nasdaq.com/articles/mid-afternoon-market-update-dow-climbs-150-points-foot-locker-shares-drop-earnings-miss", "https://www.nasdaq.com/articles/fridays-etf-movers-ilf-xbi-2017-05-19", "https://www.nasdaq.com/articles/thursdays-etf-movers-kre-xbi-2017-03-30", "https://www.nasdaq.com/articles/mid-day-market-update-crude-oil-2-halozyme-therapeutics-shares-plunge-2017-05-19", "https://www.nasdaq.com/articles/heres-why-halozyme-therapeutics-inc-falling-2017-03-30", "https://www.nasdaq.com/articles/commit-purchase-halozyme-therapeutics-8-earn-94-using-options-2017-03-21", "https://www.nasdaq.com/articles/10-small-cap-stocks-that-could-double-in-the-next-3-months-2017-03-21", "https://www.nasdaq.com/articles/notable-thursday-option-activity-halo-tif-wdc-2017-03-16", "https://www.nasdaq.com/articles/5-small-cap-biotech-stocks-buy-march-2017-03-02", "https://www.nasdaq.com/articles/why-halozyme-therapeutics-halo-might-surprise-this-earnings-season-2017-02-27", "https://www.nasdaq.com/articles/noteworthy-tuesday-option-activity-panw-yelp-halo-2017-02-14", "https://www.nasdaq.com/articles/thursday-sector-laggards-drugs-biotechnology-stocks-2017-03-30", "https://www.nasdaq.com/articles/5-small-cap-biotech-stocks-buy-february-2017-01-25", "https://www.nasdaq.com/articles/nektar-therapeutics-undervalued-biopharmaceuticals-company-plenty-pipeline-2017-01-20", "https://www.nasdaq.com/articles/halozyme-therapeutics-reaches-analyst-target-price-2017-01-10", "https://www.nasdaq.com/articles/halozyme-therapeutics-halo-in-focus%3A-stock-up-6.4-2017-01-10", "https://www.nasdaq.com/articles/heres-why-halozyme-therapeutics-fell-much-111-today-2017-01-10", "https://www.nasdaq.com/articles/can-the-rally-in-halozyme-halo-shares-continue-2017-01-09", "https://www.nasdaq.com/articles/why-halozyme-therapeutics-inc-fell-406-2016-2017-01-06", "https://www.nasdaq.com/articles/why-halozyme-therapeutics-inc-jumped-156-january-2017-02-02", "https://www.nasdaq.com/articles/halozyme-halo-up-on-positive-phase-ii-data-on-pegph20-2017-01-06", "https://www.nasdaq.com/articles/why-halozyme-therapeutics-inc-rising-today-2017-01-05", "https://www.nasdaq.com/articles/wall-street-tips-lower-jobless-claims-fall-more-expected-2017-01-05", "https://www.nasdaq.com/articles/pre-market-most-active-jan-5-2017-halo-hlx-icl-jcp-siri-m-bac-kss-nvda-myl-tvix-gnca-2017", "https://www.nasdaq.com/articles/us-futures-nudge-lower-ahead-jobs-services-data-2017-01-05", "https://www.nasdaq.com/articles/why-barrick-gold-halozyme-therapeutics-and-ceb-jumped-today-2017-01-05", "https://www.nasdaq.com/articles/halo-crosses-below-key-moving-average-level-2016-12-22", "https://www.nasdaq.com/articles/halozyme-therapeutics-halo-worth-a-look%3A-stock-up-18-2017-01-06", "https://www.nasdaq.com/articles/halozyme-halo-up-on-positive-phase-ii-data-on-pegph20-2017-01-06", "https://www.nasdaq.com/articles/why-halozyme-therapeutics-inc-rising-today-2017-01-05", "https://www.nasdaq.com/articles/why-halozyme-therapeutics-inc-stock-jumped-212-september-2016-10-10", "https://www.nasdaq.com/articles/stocks-rebound-on-deutsche-bank-rumors-2016-09-30", "https://www.nasdaq.com/articles/halozyme-therapeutics-inc.-halo-keeping-good-company-2016-09-30", "https://www.nasdaq.com/articles/halozyme-therapeutics-halo-catches-eye%3A-stock-up-7.9-2016-09-19", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-jbl-halo-calx-2016-12-16", "https://www.nasdaq.com/articles/heres-why-these-biopharma-stocks-soared-least-10-today-2016-11-09", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-higher-devon-energy-sell-non-core-upstream-assets", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-horizon-pharma-incyte-juno-therapeutics-halozyme", "https://www.nasdaq.com/articles/earnings-reaction-history-halozyme-therapeutics-inc-429-follow-through-indicator-56", "https://www.nasdaq.com/articles/noteworthy-tuesday-option-activity-wetf-halo-ppc-2016-04-19", "https://www.nasdaq.com/articles/trade-of-the-day%3A-halozyme-therapeutics-inc.-nasdaq%3Ahalo-2016-04-18", "https://www.nasdaq.com/articles/3-small-cap-stocks-buy-september-2016-08-31", "https://www.nasdaq.com/articles/earnings-reaction-history-halozyme-therapeutics-inc-500-follow-through-indicator-119", "https://www.nasdaq.com/articles/halozyme-therapeutics-now-oversold-2016-02-18", "https://www.nasdaq.com/articles/why-halozyme-therapeutics-inc-plunged-51-january-2016-02-06", "https://www.nasdaq.com/articles/how-pieces-add-iyh-targets-175-2016-02-04", "https://www.nasdaq.com/articles/1-thing-i-wish-someone-had-told-me-when-i-first-started-investing-2016-01-24", "https://www.nasdaq.com/articles/halozyme-gets-%245m-as-abbvie-begins-dosing-in-humira-trial-2016-01-22", "https://www.nasdaq.com/articles/halozyme-therapeutics-halo-in-focus%3A-stock-rises-6.7-2016-01-21", "https://www.nasdaq.com/articles/health-care-sector-update-03012016-halo-nstg-rmti-2016-03-01", "https://www.nasdaq.com/articles/wednesdays-etf-movers-nanr-xbi-2016-01-13", "https://www.nasdaq.com/articles/mid-afternoon-market-update-dow-tumbles-over-300-points-cyberark-shares-gain-following", "https://www.nasdaq.com/articles/halozyme-therapeutics-halo-in-focus%3A-stock-tumbles-16.7-2016-01-12", "https://www.nasdaq.com/articles/halozyme-therapeutics-now-oversold-halo-2016-01-11", "https://www.nasdaq.com/articles/health-care-sector-update-01112016-orex-halo-2016-01-11", "https://www.nasdaq.com/articles/why-halozyme-therapeutics-inc-rose-76-2015-2016-01-09", "https://www.nasdaq.com/articles/halozyme-raises-funds-to-support-ongoing-oncology-studies-2016-01-05", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-down-jpmorgan-beats-q4-expectations-2016-01-14", "https://www.nasdaq.com/articles/wednesdays-etf-movers-nanr-xbi-2016-01-13", "https://www.nasdaq.com/articles/halo-january-2018-options-begin-trading-2015-11-16", "https://www.nasdaq.com/articles/earnings-reaction-history-halozyme-therapeutics-inc-400-follow-through-indicator-129", "https://www.nasdaq.com/articles/why-halozyme-therapeutics-inc-heading-lower-today-2015-11-10", "https://www.nasdaq.com/articles/bullish-two-hundred-day-moving-average-cross-halo-2015-11-04", "https://www.nasdaq.com/articles/3-biotechs-play-well-others-2015-10-01", "https://www.nasdaq.com/articles/halozyme-inks-collaboration-deal-with-eli-lilly-for-enhanze-2015-12-22", "https://www.nasdaq.com/articles/why-halozyme-therapeutics-inc-jumped-13-november-2015-12-05", "https://www.nasdaq.com/articles/halozyme-therapeutics-inc-rose-14-october-heres-why-2015-11-18", "https://www.nasdaq.com/articles/oversold-conditions-halozyme-therapeutics-halo-2015-08-20", "https://www.nasdaq.com/articles/why-halozyme-shares-jumped-10-today-2015-08-11", "https://www.nasdaq.com/articles/after-hours-earnings-report-august-10-2015-bap-iff-vips-xon-fnv-rax-sf-praa-kite-nvax-halo", "https://www.nasdaq.com/articles/first-week-march-2016-options-trading-halozyme-therapeutics-halo-2015-07-21", "https://www.nasdaq.com/articles/can-the-uptrend-continue-for-halozyme-therapeutics-halo-tale-of-the-tape-2015-07-15", "https://www.nasdaq.com/articles/why-shares-halozyme-therapeutics-inc-plunged-24-august-2015-09-12", "https://www.nasdaq.com/articles/halozyme-abbvie-ink-deal-for-enhanze-platform-shares-up-analyst-blog-2015-06-04", "https://www.nasdaq.com/articles/why-shares-halozyme-therapeutics-inc-are-soaring-higher-2015-06-01", "https://www.nasdaq.com/articles/halozyme-to-advance-pegph20-following-fda-meet-analyst-blog-2015-04-09", "https://www.nasdaq.com/articles/commit-buy-halozyme-therapeutics-10-earn-155-using-options-2015-03-31", "https://www.nasdaq.com/articles/how-one-bull-playing-halozyme-2015-03-18", "https://www.nasdaq.com/articles/halozyme-q4-loss-narrower-than-expected-revenues-up-analyst-blog-2015-03-03", "https://www.nasdaq.com/articles/after-hours-earnings-report-march-2-2015-panw-slxp-xon-gwre-praa-alex-halo-mtdr-czr-ntk", "https://www.nasdaq.com/articles/can-halozyme-therapeutics-halo-run-higher-on-strong-earnings-estimate-revisions-tale-of", "https://www.nasdaq.com/articles/health-care-sector-update-12242014-halo-bdsi-endp-2014-12-24", "https://www.nasdaq.com/articles/halo-crosses-above-key-moving-average-level-2014-12-19", "https://www.nasdaq.com/articles/halozyme-up-on-collaboration-and-licensing-deal-with-jj-analyst-blog-2014-12-18", "https://www.nasdaq.com/articles/can-pfizers-cholesterol-drug-catch-competition-2014-12-11", "https://www.nasdaq.com/articles/first-week-halo-june-2015-options-trading-2014-10-27", "https://www.nasdaq.com/articles/actelion-misses-q3-earnings-expectation-ups-2014-guidance-analyst-blog-2014-10-22", "https://www.nasdaq.com/articles/vertex-pharmaceuticals-kalydeco-wins-fda-panel-backing-analyst-blog-2014-10-22", "https://www.nasdaq.com/articles/xbi-fmi-exel-halo-large-inflows-detected-etf-2015-02-27", "https://www.nasdaq.com/articles/newlink-roche-ink-deal-for-oncology-candidate-development-analyst-blog-2014-10-21", "https://www.nasdaq.com/articles/regeneron-pharmaceuticals-regn-jumps%3A-stock-up-8.5-tale-of-the-tape-2014-10-20", "https://www.nasdaq.com/articles/amicus-reports-additional-positive-data-on-fabry-therapy-analyst-blog-2014-10-20", "https://www.nasdaq.com/articles/novavax-nvax-moves-up%3A-stock-adds-10.1-in-session-tale-of-the-tape-2014-10-17", "https://www.nasdaq.com/articles/what-falling-estimates-price-mean-for-enzo-biochem-enz-tale-of-the-tape-2014-10-17", "https://www.nasdaq.com/articles/lexicon-pharmaceuticals-lxrx-jumps%3A-stock-rises-15.7-tale-of-the-tape-2014-10-17", "https://www.nasdaq.com/articles/ultragenyx-reports-data-from-sialic-acid-deficiency-study-analyst-blog-2014-10-17", "https://www.nasdaq.com/articles/biogens-q3-earnings-top-estimates-view-raised-again-analyst-blog-2014-10-22", "https://www.nasdaq.com/articles/peregrine-pharmaceuticals-pphm-jumps%3A-stock-rises-10.7-tale-of-the-tape-2014-10-16", "https://www.nasdaq.com/articles/newlink-genetics-nlnk-shows-strength%3A-stock-up-23.7-tale-of-the-tape-2014-10-14", "https://www.nasdaq.com/articles/prosensa-holding-n.v.-rna-in-focus%3A-stock-up-8.5-tale-of-the-tape-2014-10-14", "https://www.nasdaq.com/articles/halozymes-pegph20-receives-fda-orphan-drug-designation-analyst-blog-2014-10-07", "https://www.nasdaq.com/articles/halozymes-pegph20-study-s1313-clinical-hold-lifted-by-fda-analyst-blog-2014-09-19", "https://www.nasdaq.com/articles/halozyme-therapeutics-halo-jumps%3A-stock-up-9.3-tale-of-the-tape-2014-09-18", "https://www.nasdaq.com/articles/baxter-and-halozyme-therapeutics-get-fda-approval-analyst-blog-2014-09-15", "https://www.nasdaq.com/articles/mannkind-mnkd-worth-watching%3A-stock-gains-12.9-tale-of-the-tape-2014-10-16", "https://www.nasdaq.com/articles/sector-update-health-care-2014-09-15-0", "https://www.nasdaq.com/articles/why-you-shouldnt-bet-against-halozyme-therapeutics-halo-stock-tale-of-the-tape-2014-09-08", "https://www.nasdaq.com/articles/halozymes-pegph20-program-gains-fast-track-designation-analyst-blog-2014-09-05", "https://www.nasdaq.com/articles/halozyme-gains-on-narrower-than-expected-loss-revenues-up-analyst-blog-2014-08-14", "https://www.nasdaq.com/articles/earnings-reaction-history-halozyme-therapeutics-inc-333-follow-through-indicator-150", "https://www.nasdaq.com/articles/biotech-stock-roundup-biogen-hemophilia-drug-approved-ariad-halozyme-clinical-hold-lifted", "https://www.nasdaq.com/articles/pre-market-most-active-jun-5-2014-rad-s-rcap-auy-alu-cien-qqq-xiv-halo-fb-znga-mrvl-2014", "https://www.nasdaq.com/articles/sector-update-health-care-stocks-mixed-baxter-international-halo-therapeutics-declining", "https://www.nasdaq.com/articles/sector-update-healthcare-healthcare-2014-06-05", "https://www.nasdaq.com/articles/halozyme-study-clinical-hold-lifted-by-fda-analyst-blog-2014-06-05", "https://www.nasdaq.com/articles/mid-day-market-update-us-stocks-surge-pvh-shares-slip-downbeat-results-2014-06-05", "https://www.nasdaq.com/articles/thursdays-etf-movers-xbi-ewd-2014-06-05", "https://www.nasdaq.com/articles/after-hours-most-active-jun-4-2014-wy-ally-wfm-frx-xom-rf-pl-intc-cmcsa-msft-qqq-halo-2014", "https://www.nasdaq.com/articles/halozyme-therapeutics-inc.-halo-in-focus%3A-stock-up-6.9-tale-of-the-tape-2014-05-14", "https://www.nasdaq.com/articles/mid-day-market-update-rackspace-gains-upbeat-earnings-dxp-enterprises-shares-slip-2014-05", "https://www.nasdaq.com/articles/sector-update-technology-shares-flat-pre-market-clovis-oncology-upgraded-buy-stifel", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-gain-elizabeth-arden-explore-strategic-alternatives-2014", "https://www.nasdaq.com/articles/pre-market-most-active-may-13-2014-alu-nrf-ing-oks-fb-dtv-bac-hsbc-qqq-fcel-halo-gmcr-2014", "https://www.nasdaq.com/articles/mid-afternoon-market-update-markets-trade-choppy-session-elizabeth-arden-shares-remain", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-gain-johnson-johnson-profit-beats-street-view-2014-04-15", "https://www.nasdaq.com/articles/healthcare-stocks-declining-again-halozyme-giving-back-early-gains-linked-citigroup-buy", "https://www.nasdaq.com/articles/sector-update-healthcare-2014-04-15-0", "https://www.nasdaq.com/articles/halozyme-study-under-clinical-hold-analyst-blog-2014-04-10", "https://www.nasdaq.com/articles/halozymes-q1-loss-widens-analyst-blog-2014-05-13", "https://www.nasdaq.com/articles/sector-update-health-care-shares-higher-pre-market-intuitive-surgical-9-q1-guidance-2014", "https://www.nasdaq.com/articles/pre-market-most-active-apr-9-2014-nok-fb-siri-aa-vz-qqq-sny-bac-gm-halo-vod-fcel-2014-04", "https://www.nasdaq.com/articles/halozyme-falls-on-phase-ii-study-halt-analyst-blog-2014-04-08", "https://www.nasdaq.com/articles/mid-day-market-update-nasdaq-tumbles-18-synnex-shares-gain-after-upbeat-results-2014-04-04", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-mixed-carmax-results-miss-estimates-2014-04-04", "https://www.nasdaq.com/articles/us-stocks-poised-higher-close-week-mylan-reportedly-eyes-swedish-rival-2014-04-04", "https://www.nasdaq.com/articles/stock-futures-edge-higher-even-payroll-growth-slows-jobless-rate-flat-67-2014-04-04", "https://www.nasdaq.com/articles/sector-update-healthcare-2014-04-09-1", "https://www.nasdaq.com/articles/fridays-etf-movers-gdxj-xbi-2014-04-04", "https://www.nasdaq.com/articles/mid-afternoon-market-update-markets-drop-lead-lower-nasdaq-momentum-names-2014-04-04", "https://www.nasdaq.com/articles/ec-approves-roche-halozymes-mabthera-sc-analyst-blog-2014-03-31", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-open-higher-uti-worldwide-reports-q4-loss-2014-03-31", "https://www.nasdaq.com/articles/notable-two-hundred-day-moving-average-cross-halo-2014-03-27", "https://www.nasdaq.com/articles/positive-data-on-halozyme-candidate-analyst-blog-2014-03-26", "https://www.nasdaq.com/articles/cara-therapeutics-cara-zooms%3A-stock-up-12.4-tale-of-the-tape-2014-02-28", "https://www.nasdaq.com/articles/pre-market-most-active-apr-4-2014-mu-bac-qqq-seas-halo-wmc-fb-vod-myl-alu-apc-bbl-2014-04", "https://www.nasdaq.com/articles/mid-afternoon-market-update-markets-take-sharp-dip-downside-traders-take-month-end-profits", "https://www.nasdaq.com/articles/halozymes-q4-loss-wider-than-expected-analyst-blog-2014-02-28", "https://www.nasdaq.com/articles/after-hours-most-active-feb-19-2014-bac-qqq-c-tsla-cig-pbra-pbr-swy-mu-wen-fb-halo-2014-02", "https://www.nasdaq.com/articles/pre-market-most-active-feb-5-2014-nok-halo-bac-san-jcp-xiv-lpl-tvix-qqq-vale-fb-intc-2014", "https://www.nasdaq.com/articles/good-news-for-halozyme-analyst-blog-2014-01-27", "https://www.nasdaq.com/articles/pipeline-updates-from-halozyme-therapeutics-analyst-blog-2014-01-14", "https://www.nasdaq.com/articles/halozyme-therapeutics-halo-jumps%3A-stock-up-16.6-tale-of-the-tape-2013-12-19", "https://www.nasdaq.com/articles/bluebird-bio-blue-zooms%3A-stock-up-7.2-tale-of-the-tape-2014-02-28", "https://www.nasdaq.com/articles/largest-option-trades-equities-2013-12-18", "https://www.nasdaq.com/articles/sector-update-healthcare-shares-mixed-halozyme-surges-10-q3-results-2013-11-08", "https://www.nasdaq.com/articles/sector-update-healthcare-2013-11-08-1", "https://www.nasdaq.com/articles/viropharma-beats-by-a-penny-analyst-blog-2013-11-01", "https://www.nasdaq.com/articles/is-this-the-top-for-halozyme-therapeutics-inc.-halo-tale-of-the-tape-2013-10-03", "https://www.nasdaq.com/articles/halozyme-halo-in-focus%3A-stock-rises-6.9-analyst-blog-2013-09-30", "https://www.nasdaq.com/articles/sector-update-healthcare-shares-down-pre-market-nektar-loses-22-after-phase-2-study", "https://www.nasdaq.com/articles/bulls-make-fast-money-halozyme-2013-12-19", "https://www.nasdaq.com/articles/insiders-buy-aircastle-and-halozyme-while-orbitz-worldwide-sees-major-sale-2013-08-15", "https://www.nasdaq.com/articles/loss-widens-at-halozyme-in-q2-analyst-blog-2013-08-08", "https://www.nasdaq.com/articles/vphm-misses-on-earnings-revs-analyst-blog-2013-08-02", "https://www.nasdaq.com/articles/pre-market-most-active-aug-1-2013-dell-jcp-bac-sune-fb-alu-sxc-bcrx-xom-arna-myl-halo-2013", "https://www.nasdaq.com/articles/benzinga-market-wrap-thursday-august-1-record-highs-2013-08-01", "https://www.nasdaq.com/articles/halozyme-therapeutics-inc-bulls-see-lofty-gains-ahead-2013-06-25", "https://www.nasdaq.com/articles/mid-afternoon-market-update-optimer-falls-halozyme-rockets-upwards-2013-05-16", "https://www.nasdaq.com/articles/sector-update-healthcare-2013-09-27", "https://www.nasdaq.com/articles/viropharma-reports-loss-in-1q-analyst-blog-2013-05-02", "https://www.nasdaq.com/articles/market-wrap-friday-march-22-stocks-rise-hopes-bailout-deal-cyprus-2013-03-22", "https://www.nasdaq.com/articles/mid-day-market-update-micron-surges-upbeat-revenue-informatica-declines-2013-03-22", "https://www.nasdaq.com/articles/viropharma-tops-on-all-fronts-analyst-blog-2013-02-28", "https://www.nasdaq.com/articles/largest-option-buying-equities-so-far-2013-01-30", "https://www.nasdaq.com/articles/one-biotech-stock-investors-are-unfairly-ignoring-2013-01-15", "https://www.nasdaq.com/articles/upbeat-2013-from-viropharma-analyst-blog-2013-01-08", "https://www.nasdaq.com/articles/mid-day-market-update-us-stocks-fluctuate-cisco-systems-better-expected-earnings-2013-05", "https://www.nasdaq.com/articles/viropharma-reports-loss-in-1q-analyst-blog-2013-05-02", "https://www.nasdaq.com/articles/viropharma-presents-cinryze-data-analyst-blog-2012-11-14", "https://www.nasdaq.com/articles/revenues-fall-at-viropharma-analyst-blog-2012-10-29", "https://www.nasdaq.com/articles/pertaining-to-relief-for-viropharma-analyst-blog-2012-09-25", "https://www.nasdaq.com/articles/viropharma-misses-zacks-estimates-analyst-blog-2012-08-10", "https://www.nasdaq.com/articles/vphm-manufacturing-process-approved-analyst-blog-2012-08-07", "https://www.nasdaq.com/articles/pfizer-signs-a-couple-of-deals-analyst-blog-2012-12-26", "https://www.nasdaq.com/articles/pre-market-most-active-dec-21-2012-bac-rimm-itub-qqq-nok-tot-siri-c-fb-nj-halo-asca-2012", "https://www.nasdaq.com/articles/mid-afternoon-update-herbalife-takes-bigger-beating-markets-still-red-2012-12-21", "https://www.nasdaq.com/articles/viropharma-presents-cinryze-data-analyst-blog-2012-11-14", "https://www.nasdaq.com/articles/legendary-biotech-investor-just-spent-14-million-stock-2012-04-17", "https://www.nasdaq.com/articles/vphm-halo-report-encouraging-data-analyst-blog-2012-03-19", "https://www.nasdaq.com/articles/viropharmas-cinryze-reaches-uk-analyst-blog-2012-03-12", "https://www.nasdaq.com/articles/viropharma-beats-all-set-to-shine-analyst-blog-2012-03-02", "https://www.nasdaq.com/articles/bad-news-for-viropharma-analyst-blog-2012-08-03", "https://www.nasdaq.com/articles/top-stocks-big-potential-catch-moves-screen-week-2012-01-17", "https://www.nasdaq.com/articles/zackscom-featured-expert-kevin-matras-highlights-brookfield-office-properties-inc-fiserv", "https://www.nasdaq.com/articles/priority-review-for-vphms-drug-analyst-blog-2012-01-16", "https://www.nasdaq.com/articles/viropharmas-seizure-drug-reaches-uk-analyst-blog-2011-12-14", "https://www.nasdaq.com/articles/viropharma-halozyme-drug-advances-analyst-blog-2011-12-07", "https://www.nasdaq.com/articles/value-ideas-top-10-options-market-picks-trading-well-below-target-price-2011-11-15", "https://www.nasdaq.com/articles/top-20-most-undervalued-healthcare-stocks-target-price-2011-01-14", "https://www.nasdaq.com/articles/update-on-vphms-industrial-facility-analyst-blog-2012-02-09", "https://www.nasdaq.com/articles/tuesday-losers-anadarko-regal-cinemas-and-halozyme-2010-06-01"], "Content": []}